Valuation : Rekvina Laboratories Limited

Market Cap 218M 2.28M 1.96M 1.83M 1.68M 3.16M 3.17M 21.71M 8.49M 110M 8.57M 8.38M 363M P/E 2024
-167x
P/E 2025 -19.6x
Enterprise Value 220M 2.3M 1.98M 1.85M 1.7M 3.2M 3.2M 21.93M 8.57M 111M 8.65M 8.47M 367M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
-
Yield 2024 *
-
Yield 2025 -
14/08 Rekvina Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
13/08 Rekvina Laboratories Limited Announces Appointment of Surbhit Shah as Chairman of the Board CI
14/07 Surbhit Mukesh Shah, the managing director of Rekvina Laboratories Limited, Amit Mukesh Shah, the director of Rekvina Laboratories Limited and Dhruvalkumar Patel completed the acquisition of an additional 23.22% stake in Rekvina Laboratories Limited for INR 14.41 million. CI
22/05 Rekvina Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
16/03 Rekvina Laboratories Limited entered into agreement to acquire Radiant Parenterals Limited from Surbhit Mukesh Shah, Amit Mukesh Shah, Dhruvalkumar Patel, Krima Surbhit Shah and Ami Amit Shah for approximately INR 140 million. CI
16/03 Surbhit Mukesh Shah and Amit Mukesh Shah, the directors of Rekvina Laboratories Limited and Dhruvalkumar Patel proposed to acquire an additional 47.94% stake in Rekvina Laboratories Limited for INR 28.9 million. CI
11/03 Rekvina Laboratories Limited announced that it expects to receive INR 4.6 million in funding CI
06/02 Rekvina Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
29/01 Rekvina Laboratories Limited Announces the Resignation of Chetanbhai Jayantibhai Patel as Non- Executive Independent Director and from Membership in Various Committees, Effective from 29 January 2026 CI
09/01 Rekvina Laboratories Limited Announces Resignation of Dhruvalkumar Jayantilal Patel as Non-Executive Independent Director, Effective January 9, 2026 CI
14/11 Rekvina Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
20/09/25 Rekvina Laboratories Limited Announces Shifting of the Registered Office CI
13/08/25 Rekvina Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
1 day+1.99%
1 week+16.98%
Current month+95.12%
1 month+92.65%
3 months+21.49%
6 months+83.31%
Current year+984.00%
1 week 39.62
Extreme 39.62
48.78
1 month 25
Extreme 25
48.78
Current year 6.75
Extreme 6.75
48.78
1 year 6.75
Extreme 6.75
48.78
3 years 6.75
Extreme 6.75
48.78
5 years 3.8
Extreme 3.8
48.78
10 years 3.6
Extreme 3.6
48.78
Manager TitleAgeSince
Chief Executive Officer 44 22/05/2024
Director of Finance/CFO 42 02/09/2024
Compliance Officer - 04/12/2024
Director TitleAgeSince
Director/Board Member 44 01/08/2000
Director/Board Member 24 22/05/2024
Director/Board Member 42 02/09/2024

Financials

2024 2025
Net sales - -
Net income -164K -1.72K -1.47K -1.38K -1.26K -2.38K -2.39K -16.34K -6.39K -82.65K -6.45K -6.31K -274K -1.37M -14.35K -12.32K -11.54K -10.56K -19.9K -19.96K -137K -53.4K -691K -53.9K -52.73K -2.29M
Net Debt 798K 8.36K 7.17K 6.71K 6.15K 11.58K 11.62K 79.51K 31.08K 402K 31.37K 30.69K 1.33M 2.22M 23.22K 19.93K 18.66K 17.09K 32.19K 32.29K 221K 86.39K 1.12M 87.19K 85.31K 3.7M
Date Price Change Volume
28/08/26 INR 48.78 +1.99% 786
27/08/26 INR 47.83 +1.98% 1,327
26/08/26 INR 46.90 +1.98% 1,582
25/08/26 INR 45.99 +5.00% 6,476
24/08/26 INR 43.80 +4.99% 4,853
  1. Stock Market
  2. Stocks
  3. VINRKLB Stock